Pulse Biosciences (NASDAQ:PLSE) Raised to “Sell” at StockNews.com

Pulse Biosciences (NASDAQ:PLSEGet Rating) was upgraded by research analysts at StockNews.com to a “sell” rating in a note issued to investors on Thursday.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright cut Pulse Biosciences from a “buy” rating to a “neutral” rating in a research note on Friday, May 13th. Stephens lowered Pulse Biosciences from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 12th.

Pulse Biosciences Stock Down 0.6 %

Shares of Pulse Biosciences stock opened at $1.59 on Thursday. Pulse Biosciences has a 52 week low of $1.41 and a 52 week high of $29.16. The firm’s 50 day moving average is $1.89 and its two-hundred day moving average is $4.18. The firm has a market capitalization of $47.39 million, a P/E ratio of -0.74 and a beta of 1.94.

Pulse Biosciences (NASDAQ:PLSEGet Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $0.70 million. As a group, research analysts expect that Pulse Biosciences will post -1.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of PLSE. Advisor Group Holdings Inc. grew its holdings in shares of Pulse Biosciences by 25.5% in the 1st quarter. Advisor Group Holdings Inc. now owns 25,878 shares of the company’s stock worth $126,000 after acquiring an additional 5,265 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Pulse Biosciences during the fourth quarter valued at $164,000. Westside Investment Management Inc. grew its holdings in shares of Pulse Biosciences by 41.4% during the second quarter. Westside Investment Management Inc. now owns 178,195 shares of the company’s stock valued at $272,000 after buying an additional 52,166 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Pulse Biosciences during the first quarter valued at $378,000. Finally, Bank of America Corp DE grew its holdings in shares of Pulse Biosciences by 5.1% during the first quarter. Bank of America Corp DE now owns 820,390 shares of the company’s stock valued at $3,988,000 after buying an additional 39,645 shares in the last quarter. 13.63% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

(Get Rating)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.